
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics is currently in a strong position for future growth with anticipated revenue increases and positive feedback from medical associations regarding their EsoGuard product, which has a potential $60 billion market. The company is also actively expanding their sales force and has a backlog of $40 million along with a potential $2 billion market opportunity for their EsoGuard test. While there are potential risks, analysts have a Buy rating on the stock and it is currently undervalued at a price of $2.50.
Bears say
Lucid Diagnostics is facing multiple challenges, including a decrease in EsoGuard tests processed in the first quarter of 2025, deferred revenue recognition, and a potentially smaller market opportunity compared to its estimated $2 billion. In addition, the company is still in its early stages of commercialization and has not yet gained Medicare coverage. There are also risks associated with obtaining regulatory approvals, gaining reimbursement from commercial payors, and competition in the medical diagnostics industry. These challenges pose significant risks to the company's financial performance and the attainment of its share price target.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares